Cell & Gene Therapies
Project Purpose
Cell and gene therapies arouse and are slowly growing and these types of therapies require specialized logistics such as real-time monitoring of temperature, storage, security, etc. The logistic sector needs to adapt and communicate with the developers and manufacturers to understand each other’s language and define together the best and most efficient transport solutions.
Project Objective(s)
The main objective of this project is to broaden the current knowledge of air transportation of BioPharma and CGT (Cellular Therapy and Gene Therapy) products.
Project Status And Key-takeaways
Project ongoing, following the steps:
-
Work Package 1: Host and exclusive webinar for the members of both organisations (Pharma.Aero and HLA) on June 15, 2021, followed by a survey. The results of the survey and insights gathered amongst the presenters, the attendees and the project group were outlined in a White Paper. This first report examined the competitive positioning of UAV against other transportation modes, the regulatory framework for drone operations and applications of UAV in the Pharma and Humanitarian Air Cargo sector.
-
Work Package 2: Create a 360° interactive video to showcase drone lab technologies, different types of drones and drone operations. This video is now available for Pharma.Aero members only.
-
Work Package 3: Map the journey of the Covid-19 vaccines from the manufacture point in Europe to the arm of the patient in Malawi. Draft a list of recommendations on how to optimize the end-to-end transportation by shortening the supply chain and linking both traditional airfreight and drone worlds. Disseminate a theoretical proof of concept (technical report and white paper). See here the video of the Vaccines transportation from Belgium to Malawi.
PROJECT
SUPPORT AND
COLLABORATION.
- Pharma.Aero Board liaison: Edmonton Airport
- Project lead: Milton De la Paz, DFW (Dallas Fort Worth)
- Project members: Pharma.Aero members and partners participating in the survey
- Project external support: BioNTX (Bio North Texas), GeneTether Therapeutics, Taysha Gene Therapies
- Project manager and expert: Franck Toussaint, BSMA (external consultant)